Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Highlights From the Annual Meeting of the American Epilepsy Society 2022
Valencia, Ignacio , Alexander, Allyson , Andrade, Danielle M. , Arévalo, Miguel , Auer, Nancy A. , Bartoloméi, Fabrice , Becker, Danielle A. , Bernasconi, Andrea , Bernasconi, Neda , Bhatnagar, Shivani , Blumenfeld, Hal , Burdette, David E. , Conner, Kelly , Conway, Jeannine M. , Diaz-Arastia, Ramon, Drees, Cornelia , French, Jacqueline A. , Ganguly, Taneeta M. , Gotman, Jean , Guilfoyle, Shanna M., Gupta, Gita , Hentges, Katie, Huh, Linda , Kelley, Sarah A. , Vega‐Talbott, Maite La, Lam, Alice , Lowenstein, Daniel H. , Maturu, Sarita , McDonald, Carrie R. , McKee, Heather , Meador, Kimford J. , Michael, Elizabeth H., Mikati, Mohamad A. , Mitchell, James , Myers, Leah S. , Naritoku, Dean K., Neville, Kerri, Pavlova, Milena , Perry, Μ. Scott , Plueger, Madona, Pugh, Mary Jo , Quigg, Mark , Reddy, Shilpa B. , Reynolds, Tamara S. , Santana‐Gomez, Cesar , Schommer, Linsday, Shellhaas, Renée A. , Shrey, Daniel W. , Singh, Rani K. , Suleman, Saher, Templer, Jessica W. , Varadkar, Sophia , Velez‐Ruiz, Naymee , Velı́šková, Jana , Voskobiynyk, Yuliya , Wagner, Janelle L. , Wagnon, Jacy L. , Waller, Claire, Waller, Jill, Welborn, Michelle, Shellhaas, Renée A , Mikati, Mohamad A , Andrade, Danielle M , French, Jacqueline , Meador, Kimford J , Templer, Jessica W , McKee, Heather Ravvin , Ganguly, Taneeta Mindy , Burdette, David E , Valencia, Ignacio , Arevalo-Astrada, Miguel, Rubiños, Clio , Auer, Nancy, Bainbridge, Jacquelyn L. , Baxendale, Sallie , Berg, Anne T. , Bernhardt, Boris C. , Bhatnagar, Shivani, Blümcke, Ingmar , Buchanan, Gordon F. , Burneo, Jorge G. , Busch, Robyn M. , Chauvel, Patrick , Chin, Jeannie , Clifford, Lisa M. , Cook, Mark , Drees, Cornelia , Gelfand, Michael , Glauser, Tracy A. , Gleichgerrcht, Ezequiel L. , Goldman, Alica M. , González-Martínez, Jorge , Grinspan, Zachary M. , Hammer, Michael F. , Hartman, Adam L. , Hogan, R Edward , Hyslop, Ann , Jobst, Barbara C. , Josephson, Colin B. , Knupp, Kelly G. , Koepp, Matthias J. , Kothare, Sanjeev V. , Krook-Magnuson, Esther , Kwasa, Jasmine A. C. , Lee, Jong Woo , Mayor, Luis Carlos , McKhann, Guy M. , Mefford, Heather C. , Millichap, J Gordon , Noebels, Jeffrey L. , O’Brien, Terence J. , Oluigbo, Chima , Patel, Anup D. , Paz, Jeanne T. , Pennell, Page B. , Perucca, Piero , Pitkänen, Asla , Ryan, Christopher, Sajatovic, Martha , Schuele, Stephan , Sperling, Michael R. , Thom, Maria , Trinka, Eugen , Wang, Irène , Wirrell, Elaine

Mayo Clinic

Epilepsy Currents | August 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597231187227 Get It

With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.
Gastrointestinal hospitalization during COVID‐19 pandemic in the United States: Analysis of a nationwide inpatient sample
Wang, Yichen , Huang, Yuting , Zheng, Ting , Yang, Keming , Pang, Maoyin , Pang, Maoyin , Huang, Yuting , Wang, Yichen , Sun, Chenyu

Mayo Clinic

Journal of Gastroenterology and Hepatology | August 15, 2023 | Volume: 38 | Issue: 11 | Pages: 1971-1979

10.1111/jgh.16318 | PMID 37581244 Get It

AbstractBackground and AimWe aim to systematically investigate gastrointestinal (GI) hospitalizations in the United States during the early phase of the COVID‐19 pandemic on a national level and the consequence that may inform practice and policies.MethodsA retrospective cross‐sectional analysis of adult hospitalizations with GI‐related diagnoses or procedures in the United States in 2020 was used, with hospitalizations from 2016 to 2019 used for contextual information.ResultsHospitalizations with principal and secondary GI diagnoses decreased by 13.3% and 8.2% from 2019 to 2020, respectively. Most GI diagnoses decreased in 2020, with a few exceptions including alcoholic liver disease (increased by 7.8% as a principal diagnosis) and acute liver failure (increased by 11.6% as a secondary diagnosis). The mortality rate of hospitalizations with GI disease increased in 2020 compared with 2019 (for principal diagnosis: adjusted odds ratio 1.08, 95% confidence interval 1.03–1.13, P = 0.001; for secondary diagnosis: adjusted odds ratio 1.10, 95% confidence interval 1.07–1.13, P < 0.001). Most GI procedures decreased except for a notable 8.3% increase in gastrostomy. The per‐GI‐hospitalization rate of procedures increased for hospitalizations with a principal GI diagnosis (56.4% vs 55.6%, P = 0.003) or unchanged for hospitalizations with secondary GI diagnoses (18.3% vs 18.2%, P = 0.512).ConclusionThe COVID‐19 pandemic resulted in a decrease in the volume of GI hospitalizations and procedures in 2020, but there was an increase in the mortality rate and some specific diagnoses including alcoholic liver disease and acute liver failure. These findings will likely enlighten future research and healthcare resource allocation for GI diseases.
Abstract B026: Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma
Rachamala, Hari K., Dutta, Shamit K., Wang, Enfeng , Rachamalla, Hari Krishnareddy , Rachamala, Hari Krishnareddy , Pal, Krishnendu , Madamsetty, Vijay Sagar , Mukhopadhyay, Debabrata

Mayo Clinic

Cancer Research | August 15, 2023 | Volume: 83 | Issue: 16_Supplement | Pages: B026-B026

10.1158/1538-7445.kidney23-b026 Get It

Abstract Purpose: Although renal cell carcinoma (RCC) is relatively more resistant to radiation therapy (RT) compared to other cancer indications, recent advances in single-fraction and multi-fraction stereotactic ablative radiotherapy (SABR) made it possible to achieve better outcome and reduce treatment related toxicities. In addition, with studies demonstrating that certain therapeutic agents including chemotherapies can act as radiosensitizers, the idea of combining radiotherapy with those agents are being actively pursued. Among them, mammalian target of rapamycin (mTOR) inhibitor everolimus (E) and survivin inhibitor YM155 (Y) are of special interest since they target multiple RT-resistance mechanisms simultaneously. Additionally, YM155 has been shown to help in overcoming resistance to mTOR inhibitors in various cancer including RCC. Hence, the present study aims to evaluate the efficacy of a tumor-targeted liposomal formulation combining everolimus and YM155 (EY-L) in sensitizing RCC tumors towards radiation. Experimental Design: Previously we developed a tumor-targeted liposomal formulation and used it successfully to deliver multiple drugs for the treatment of RCC in both immune-deficient and immune-competent mouse models. Here we developed a similar formulation combining everolimus and YM155 (EY-L) and assessed its efficacy in RCC cell lines in vitro and in RCC tumors in vivo. We further evaluated the efficacy of EY-L in sensitizing RCC cell lines and tumors towards radiation in vitro using clonogenic assay and in vivo in RCC xenografts in immunodeficient mice and murine RCC models in immunocompetent mice. Results: EY-L (2 mg/kg E, 1.4 mg/kg Y, twice a week intravenous administration) was better than E-L or Y-L, the corresponding single drug loaded formulations in containing the primary tumor growth and improving survival in an immunocompetent syngeneic mouse model of RCC. Furthermore, EY-L leads to significantly higher sensitization of RCC cells towards radiation in vitro than E-L or Y-L. Finally, EY-L was able to sensitize RCC tumors towards radiation therapy in both RCC xenograft and murine RCC model. Conclusion: Taken together, our study demonstrated the efficacy of a strategic combination therapy in sensitizing RCC to radiation therapy using in vitro clonogenic assay and in vivo radiosensitization studies in multiple RCC tumor models. Citation Format: Krishnendu Pal, Vijay S. Madamsetty, Hari K. Rachamala, Shamit K. Dutta, Enfeng Wang, Debabrata Mukhopadhyay. Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr B026.
Cervical laminoplasty versus laminectomy and posterior cervical fusion for cervical myelopathy: propensity-matched analysis of 24-month outcomes from the Quality Outcomes Database
Mummaneni, Praveen V. , Chou, Dean , Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Haid, Regis W., Chan, Andrew K. , Michalopoulos, Giorgos , Yang, Eunice, Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | August 12, 2023 | Volume: 39 | Issue: 5 | Pages: 671-681

10.3171/2023.6.spine23345 | PMID 37728378 Get It

OBJECTIVE Compared with laminectomy with posterior cervical fusion (PCF), cervical laminoplasty (CL) may result in different outcomes for those operated on for cervical spondylotic myelopathy (CSM). The aim of this study was to compare 24-month patient-reported outcomes (PROs) for laminoplasty versus PCF by using the Quality Outcomes Database (QOD) CSM data set. METHODS This was a retrospective study using an augmented data set from the prospectively collected QOD Registry Cervical Module. Patients undergoing laminoplasty or PCF for CSM were included. Using the nearest-neighbor method, the authors performed 1:1 propensity matching based on age, operated levels, and baseline modified Japanese Orthopaedic Association (mJOA) and visual analog scale (VAS) neck pain scores. The 24-month PROs, i.e., mJOA, Neck Disability Index (NDI), VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and North American Spine Society (NASS) satisfaction scores, were compared. Only cases in the subaxial cervical region were included; those that crossed the cervicothoracic junction were excluded. RESULTS From the 1141 patients included in the QOD CSM data set who underwent anterior or posterior surgery for cervical myelopathy, 946 (82.9%) had 24 months of follow-up. Of these, 43 patients who underwent laminoplasty and 191 who underwent PCF met the inclusion criteria. After matching, the groups were similar for baseline characteristics, including operative levels (CL group: 4.0 ± 0.9 vs PCF group: 4.2 ± 1.1, p = 0.337) and baseline PROs (p > 0.05), except for a higher percentage involved in activities outside the home in the CL group (95.3% vs 81.4%, p = 0.044). The 24-month follow-up for the matched cohorts was similar (CL group: 88.4% vs PCF group: 83.7%, p = 0.534). Patients undergoing laminoplasty had significantly lower estimated blood loss (99.3 ± 91.7 mL vs 186.7 ± 142.7 mL, p = 0.003), decreased length of stay (3.0 ± 1.6 days vs 4.5 ± 3.3 days, p = 0.012), and a higher rate of routine discharge (88.4% vs 62.8%, p = 0.006). The CL cohort also demonstrated a higher rate of return to activities (47.2% vs 21.2%, p = 0.023) after 3 months. Laminoplasty was associated with a larger improvement in 24-month NDI score (−19.6 ± 18.9 vs −9.1 ± 21.9, p = 0.031). Otherwise, there were no 3- or 24-month differences in mJOA, mean NDI, VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and distribution of NASS satisfaction scores (p > 0.05) between the cohorts. CONCLUSIONS Compared with PCF, laminoplasty was associated with decreased blood loss, decreased length of hospitalization, and higher rates of home discharge. At 3 months, laminoplasty was associated with a higher rate of return to baseline activities. At 24 months, laminoplasty was associated with greater improvements in neck disability. Otherwise, laminoplasty and PCF shared similar outcomes for functional status, pain, quality of life, and satisfaction. Laminoplasty and PCF achieved similar neck pain scores, suggesting that moderate preoperative neck pain may not necessarily be a contraindication for laminoplasty.
Clinical Outcome of TAVI vs. SAVR in Patients with Severe Aortic Stenosis
Krittanawong, Chayakrit , Hahn, Joshua , Wang, Zhen , Al-Azzam, Fu’ad, Sharma, Samin K. , Jneid, Hani , Sharma, Samin K , Virk, Hafeez Ul Hassan , Alam, Mahboob

Mayo Clinic

Journal of Clinical Medicine | August 11, 2023 | Volume: 12 | Issue: 16 | Pages: 5236

10.3390/jcm12165236 | PMID 37629278 Get It

The utilization of transcatheter aortic valve implantation (TAVI) has become the treatment of choice in patients with severe aortic stenosis (AS) with intermediate-to-high surgical risk for surgical aortic valve replacement (SAVR) [...]
The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review
Gawey, Brent J. , Yang, Juan , Bauer, Brent A. , Song, Joanne, Gawey, Brent , Bauer, Brent, Wang, Xiao‐Jing

Mayo Clinic

Therapeutic Advances in Chronic Disease | August 11, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231190548 | PMID 37577106 Get It

Background: Most people with coronavirus disease 2019 (COVID-19) experience resolution of symptoms within days to weeks following initial infection. In a subset of individuals, symptoms persist longer than 4 weeks, known as ‘Long COVID’. Many gastrointestinal (GI) symptoms persist as part of this syndrome; yet, an approach to treatment remains unclear. Prior studies have demonstrated the efficacy of complementary and alternative medicine (CAM) for the treatment of acute COVID-19 infections, but little data exist regarding the potential use of CAM in the treatment of Long COVID. Objectives: Identify CAM approaches useful in treating the GI symptoms of Long COVID. Design: A systematic review of studies reporting on the use of CAM for the treatment of GI symptoms of Long COVID was performed. Data Sources and Methods: Five electronic databases were searched from January 2019 to November 2022. Studies describing the use of CAM to treat GI symptoms of Long COVID were included and assessed by two independent reviewers. Studies not reporting on GI symptoms or using CAM were excluded. Studies chosen for final review underwent quality and bias assessment using predetermined criteria. The extracted data were synthesized utilizing a framework derived from the National Center of Complementary and Integrative Health categories. Results: The initial search yielded 396 articles. After applying the eligibility criteria, a total of four studies (three case reports and one case series) were included for final review. Two studies used nutritional supplements and two studies used traditional Chinese medicine. Reductions in nausea, loss of appetite, diarrhea, acid reflux, epigastric pain, and bloating were reported. Conclusion: This is the first systematic review to explore the role of CAM in treating GI manifestations of Long COVID. The review identified four studies, all reporting reductions in the GI symptoms of Long COVID. Despite the positive studies included in this review, the overall search yielded few results, all of which were non-experimental. As the post-infectious sequelae of COVID-19 become better recognized in the wake of the pandemic, higher-quality clinical studies are needed.
P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
Coombs, Catherine C. , Shah, Nirav N. , Woyach, Jennifer A. , Maddocks, Kami J. , Muehlenbein, Catherine E. , Wang, Chunxiao , Abhyankar, Sarang, Tsai, Donald E. , Eyre, Toby A. , Jurczak, Wojciech , Cheah, Chan Y. , Patel, Krish , Wang, Yucai

Mayo Clinic

HemaSphere | August 10, 2023 | Volume: 7 | Issue: S3 | Pages: e6206253

10.1097/01.hs9.0000969376.62062.53 Get It

Effector response to necroptotic cell death: an ensemble of immune and stromal cells
Hughes, Lindsey D. , Nevin, James, Wang, Mamie, Pelorosso, Facundo, Leighton, Jonathan A. , Altun, Osman, Kluger, Yuval , Rothlin, Carla V. , Ghosh, Sourav

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 72.39-72.39

10.4049/jimmunol.210.supp.72.39 Get It

Abstract Cell death manifests through a panoply of molecular pathways. We postulated that the tissue effector response to cellular corpses is similarly diverse. Apoptotic cell death in the lung, in the context of helminth infection and an IL-4-rich environment, is sensed by macrophages to direct resolution of inflammation and a tissue repair gene expression program. Apoptotic cell death, however, is commonplace in the gut and integral to homeostatic tissue renewal in this organ. Another specific molecularly-executed cell death modality – necroptosis – has been reported in the gut in settings of non-resolving inflammation and tissue damage, such as in inflammatory bowel disease. Here we report the discovery of an effector response to necroptotic corpses (NC). Using a chemo-genetic approach to specifically trigger necroptosis in the intestinal epithelium in vivo, we compiled an atlas of transcriptomic changes at a single-cell level and compared this to inflammatory and resolving injury models. Fibroblasts and macrophages, upon encounter with NC, displayed an excessive inflammatory response. Fibroblasts are the major stromal cells that play an essential role in tissue healing by undergoing fibroblast to myofibroblast transition under the influence of TGF-β. This step is a critical event in wound healing as the contractile forces generated by myofibroblasts bring the two apposed edges of the wounded tissue together for wound closure. Exposure to NC prevented this myofibroblast transition. Taken together, these findings point to an invariant code that informs effector tissue responses based on the type, context, and sensor of cell death.
P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
Mutebi, Alex, Wang, Tongsheng , Jun, Monika, Yu, Junhua, Brodkin, Samantha, Sacchi, Mariana, Kalsekar, Anupama, Ip, Andrew , Rosenthal, Allison , Mutebi, Alex , Wang, Anthony , Muñoz, Javier

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e324937a

10.1097/01.hs9.0000971572.32493.7a Get It

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Ataei, Fatemeh , Pritchett, Josh, Shreve, Jacob , Khurana, Arushi , Nowakowski, Grzegorz S. , Thorpe, Matthew , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Wang, Yucai , Young, Jason R.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e6583552

10.1097/01.hs9.0000971504.65835.52 Get It